SA
MTNB icon

Sanctuary Advisors’s Matinas BioPharma MTNB Stock Holding History

Sanctuary Advisors’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,004
Closed -$6.16K – 2456
2024
Q3 		$6.16K Buy
10,004
+9,800
+4,804% +$62.4K ﹤0.01% 2360
2024
Q2 		$1.82K Buy
+204
New +$1.85K ﹤0.01% 2326

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HIW
Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Sanctuary Advisors's MTNB Position: Q4 2024 in Review

Sanctuary Advisors sold out of Matinas BioPharma (MTNB) in Q4 2024, closing a stake of 10,004 shares — an estimated $6.16K sold.

Sanctuary Advisors first reported a position in MTNB in Q2 2024 and held it in 2 quarters. The position peaked at $6.16K in Q3 2024. 22 funds tracked by Wall St. Rank hold MTNB as of Q4 2024.

  • Sanctuary Advisors reported no remaining Matinas BioPharma position as of Q4 2024 after selling out during the quarter.
  • Sanctuary Advisors sold 10,004 Matinas BioPharma shares in Q4 2024, an estimated $6.16K.
  • Sanctuary Advisors first reported a position in Matinas BioPharma in Q2 2024 and held it in 2 quarters.
  • Sanctuary Advisors's Matinas BioPharma position peaked at $6.16K in Q3 2024.
  • 22 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2024.

Based on Sanctuary Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.